Literature DB >> 31858220

Prognostic accuracy of different lymph node staging system in predicting overall survival in stage IV colon cancer.

Lingyu Han1,2, Shaobo Mo1,2, Wenqiang Xiang1,2, Qingguo Li1,2, Renjie Wang1,2, Ye Xu1,2, Weixing Dai3,4, Guoxiang Cai5,6.   

Abstract

PURPOSE: With emphasis of surgical management, the lymph node (LN) status has been advocated to predict prognosis in colon cancer with distant metastatic. Therefore, we tend to compare the prognostic performance of American Joint Committee on Cancer (AJCC) N-staging relative to lymph node ratio (LNR), log odds of metastatic lymph nodes (LODDS), and N-score in stage IV colon cancer.
METHODS: About 20,961 patients who underwent primary surgical resection for stage IV colon cancer were extracted from Surveillance, Epidemiology, and End Results (SEER) Program database. Harrell's C statistic (C-index) and Akaike's Information Criterion (AIC) were used to distinguish the prognostic performance of the different LN-staging schemes.
RESULTS: Of the 20,961 patients, 17,043 (81.3%) had been with lymph node metastasis, and the median number of examined lymph nodes (ELNs) was 15. When assessed as continuous values, the LODDS shown as the best system with greatest discriminatory power (C-index, 0.6241; AIC, 29114.29) generally and each subgroups divided by ELNs. When modeled as categorical cutoff variables for further clinical usage, the 8th AJCC N-stage outperformed the other three schemes with either ELNs less than 12 (C-index, 0.5770; AIC, 8992.638), between 12 and 25 (C-index, 0.6084; AIC, 13905.72), or more than 25(C-index, 0.6192; AIC, 3138.018) with increasing C-index and less AIC value.
CONCLUSIONS: When assessed as categorical variables, N-stage performed superiorly regardless of ELNs. When assessed as a continuous variable, LODDS exhibited good discriminative ability and goodness of fit in predicting survival for colon cancer patients regardless of ELNs.

Entities:  

Keywords:  Colorectal cancer; Lymph nodes; Prognostic factor; Survival analysis

Mesh:

Year:  2019        PMID: 31858220     DOI: 10.1007/s00384-019-03486-w

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  10 in total

1.  Prognostic significance of the lymph node ratio in stage IV colorectal cancer patients who have undergone curative resection.

Authors:  Tsuyoshi Ozawa; Soichiro Ishihara; Takeshi Nishikawa; Toshiaki Tanaka; Junichiro Tanaka; Tomomichi Kiyomatsu; Keisuke Hata; Kazushige Kawai; Hiroaki Nozawa; Takamitsu Kanazawa; Shinsuke Kazama; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Toshiaki Watanabe
Journal:  Ann Surg Oncol       Date:  2014-11-15       Impact factor: 5.344

2.  Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis.

Authors:  Sigmar Stelzner; Gunter Hellmich; Rainer Koch; Klaus Ludwig
Journal:  J Surg Oncol       Date:  2005-03-15       Impact factor: 3.454

3.  Regional Lymph Nodes Status and Ratio of Metastatic to Examined Lymph Nodes Correlate with Survival in Stage IV Colorectal Cancer.

Authors:  Shahid Ahmed; Anne Leis; Selliah Chandra-Kanthan; Anthony Fields; Adnan Zaidi; Tahir Abbas; Duc Le; Bruce Reeder; Punam Pahwa
Journal:  Ann Surg Oncol       Date:  2016-03-25       Impact factor: 5.344

Review 4.  Surgical Treatment of Metastatic Colorectal Cancer.

Authors:  Jeffery Chakedis; Carl R Schmidt
Journal:  Surg Oncol Clin N Am       Date:  2017-12-15       Impact factor: 3.495

5.  Log odds of positive lymph nodes as a prognostic indicator in stage IV colorectal cancer patients undergoing curative resection.

Authors:  Tsuyoshi Ozawa; Soichiro Ishihara; Eiji Sunami; Joji Kitayama; Toshiaki Watanabe
Journal:  J Surg Oncol       Date:  2015-02-17       Impact factor: 3.454

6.  Comparison of three lymph node classifications for survival prediction in distant metastatic gastric cancer.

Authors:  Rui Zhou; Jingwen Zhang; Huiying Sun; Yulin Liao; Wangjun Liao
Journal:  Int J Surg       Date:  2016-10-03       Impact factor: 6.071

7.  Nodal status, number of lymph nodes examined, and lymph node ratio: what defines prognosis after resection of colon adenocarcinoma?

Authors:  Ana L Gleisner; Harveshp Mogal; Rebecca Dodson; Jon Efron; Susan Gearhart; Elizabeth Wick; Anne Lidor; Joseph M Herman; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-09-14       Impact factor: 6.113

8.  The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient's status.

Authors:  Hae Ran Yun; Woo Yong Lee; Won Suk Lee; One Suk Lee; Yong Beom Cho; Seong Hyeon Yun; Ho-Kyung Chun
Journal:  Int J Colorectal Dis       Date:  2007-05-08       Impact factor: 2.571

9.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

10.  Surgical Management of the Primary Tumor in Stage IV Colorectal Cancer: A Confirmatory Retrospective Cohort Study.

Authors:  Shahid Ahmed; Anne Leis; Selliah Chandra-Kanthan; Anthony Fields; Bruce Reeder; Nayyer Iqbal; Kamal Haider; Duc Le; Punam Pahwa
Journal:  J Cancer       Date:  2016-04-27       Impact factor: 4.207

  10 in total
  2 in total

1.  Comparison of model fit and discriminatory ability of the 8th edition of the tumor-node-metastasis classification and the 9th edition of the Japanese classification to identify stage III colorectal cancer.

Authors:  Kei Kitamura; Dai Shida; Shigeki Sekine; Yuka Ahiko; Yuya Nakamura; Konosuke Moritani; Shunsuke Tsukamoto; Yukihide Kanemitsu
Journal:  Int J Clin Oncol       Date:  2021-06-03       Impact factor: 3.402

2.  Log odds of positive lymph nodes is a better prognostic factor for oesophageal signet ring cell carcinoma than N stage.

Authors:  Feng Wang; Shu-Geng Gao; Qi Xue; Feng-Wei Tan; Yu-Shun Gao; You-Sheng Mao; Da-Li Wang; Jun Zhao; Yin Li; Xiang-Yang Yu; Hong Cheng; Chen-Guang Zhao; Ju-Wei Mu
Journal:  World J Clin Cases       Date:  2021-01-06       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.